Third Avenue Management’s ANI Pharmaceuticals ANIP Stock Holding History

Third Avenue Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-49,933	Closed	-$2.34M	–	111
2017 Q2	$2.34M	Hold	49,933	–	–	0.1%	101
2017 Q1	$2.47M	Hold	49,933	–	–	0.11%	97
2016 Q4	$3.03M	Sell	49,933 -120	-0.2%	-$7.34K	0.14%	95
2016 Q3	$3.32M	Hold	50,053	–	–	0.15%	85
2016 Q2	$2.79M	Hold	50,053	–	–	0.12%	90
2016 Q1	$1.69M	Hold	50,053	–	–	0.06%	101
2015 Q4	$2.26M	Sell	50,053 -9,663	-16%	-$416K	0.07%	93
2015 Q3	$2.36M	Buy	59,716 +7,926	+15%	+$451K	0.06%	106
2015 Q2	$3.21M	Buy	+51,790	New	+$3.08M	0.08%	103

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Third Avenue Management's ANIP Position: Q3 2017 in Review

Third Avenue Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 49,933 shares — an estimated $2.34M sold.

Third Avenue Management first reported a position in ANIP in Q2 2015 and held it in 9 quarters. The position peaked at $3.32M in Q3 2016. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

Third Avenue Management reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Third Avenue Management sold 49,933 ANI Pharmaceuticals shares in Q3 2017, an estimated $2.34M.
Third Avenue Management first reported a position in ANI Pharmaceuticals in Q2 2015 and held it in 9 quarters.
Third Avenue Management's ANI Pharmaceuticals position peaked at $3.32M in Q3 2016.
146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Third Avenue Management's 13F filing for Q3 2017, filed 26 Oct 2017.